• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
| Market Cap | 3.323 Billion | Shares Outstanding | 33.209 Million | Avg 30-day Volume | 872.827 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
| Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | 0 |
| Price to Book Value | 6.0076 | Operating Margin | 0.0 | Enterprise Value | 1.795 Billion |
| Current Ratio | 17.014 | EPS Growth | 0 | Quick Ratio | 14.578 |
| 1 Yr BETA | 1.0296 | 52-week High/Low | 0.0 / | Profit Margin | 0.0 |
| Operating Cash Flow Growth | 0.0 | Altman Z-Score | 37.032 | Free Cash Flow to Firm | -42.766 Million |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2020-09-28 | 0 | |
|
No longer subject to file | 2020-09-28 | 0 | |
|
CHAI CHRISTOPHER Y CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2020-09-28 | 0 |
|
BABLER MARTIN PRESIDENT, CEO |
|
No longer subject to file | 2020-09-28 | 0 |
|
HARDIMAN ROY C. CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2020-09-28 | 0 |
|
No longer subject to file | 2020-09-28 | 0 | |
|
No longer subject to file | 2020-09-28 | 0 | |
|
No longer subject to file | 2020-09-28 | 0 | |
|
GOLDSTEIN DAVID M CHIEF SCIENTIFIC OFFICER |
|
No longer subject to file | 2020-09-28 | 0 |
|
WOLFF STEFANI CHIEF DEVELOPMENT OFFICER |
|
No longer subject to file | 2020-09-28 | 0 |
|
No longer subject to file | 2020-09-28 | 0 | |
|
THOMAS DOLCA CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2020-09-28 | 0 |
|
BIOTECHNOLOGY VALUE FUND II LP |
|
0 | 2020-08-18 | 0 |
|
2,982,855 | 2019-10-18 | 0 | |
|
NEW LEAF VENTURE ASSOCIATES II, L.P. NEW LEAF VENTURE MANAGEMENT II, L.L.C. NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P. |
|
No longer subject to file | 2019-08-13 | 0 |
|
No longer subject to file | 2019-05-21 | 0 | |
|
0 | 2019-02-19 | 0 | |
|
SOFINNOVA VENTURE PARTNERS VIII, L.P. |
|
2,059,146 | 2018-09-18 | 0 |
|
383,480 | 2018-09-18 | 0 | |
|
GOURLAY STEVE CHIEF MEDICAL OFFICER |
|
107,857 | 2018-09-18 | 0 |
|
0 | 2018-09-13 | 0 | |
|
0 | 2018-09-13 | 0 | |
|
0 | 2018-09-13 | 0 | |
|
3,945 | 2018-09-13 | 0 | |
|
0 | 2018-09-13 | 0 | |
|
0 | 2018-09-13 | 0 | |
|
0 | 2018-09-13 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Trust for Professional Managers- Convergence Market Neutral Fund | PRNB | -668.0 shares, $-66806.68 | 2020-08-31 | N-PORT |
| FundVantage Trust- Gotham Enhanced Index Plus Fund | PRNB | -91.0 shares, $-5403.58 | 2020-03-31 | N-PORT |
| FundVantage Trust- Gotham Defensive Long Fund | PRNB | -10.0 shares, $-593.8 | 2020-03-31 | N-PORT |
| FundVantage Trust- Gotham Index Plus All-Cap Fund | PRNB | -108.0 shares, $-6413.04 | 2020-03-31 | N-PORT |
